Working… Menu
Trial record 78 of 728 for:    Area Under Curve AND Bioavailability

Pilot BA Study of New LY03005 vs Pristiq

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02988024
Recruitment Status : Completed
First Posted : December 9, 2016
Last Update Posted : March 20, 2017
Information provided by (Responsible Party):
Luye Pharma Group Ltd.

Brief Summary:
The objects of this study is to assess the relative bioavailability (BA) of 80 mg LY03005 oral tablets compared to 50 mg Pristiq® oral tablets after a single oral intake under fasting conditions in healthy subjects between 18 and 50 years of age.

Condition or disease Intervention/treatment Phase
Major Depression Drug: LY03005 Drug: Pristiq Phase 1

Detailed Description:
Twenty (20) eligible subjects will be enrolled and assigned to either LY03005 group or Pristiq group at a 1:1 ratio at one site in the USA.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Single-Dose Study to Assess the Relative Bioavailability of LY03005 Oral Tablets Versus Pristiq Oral Tablets Under Fasting Conditions in Healthy Subjects
Actual Study Start Date : December 7, 2016
Actual Primary Completion Date : December 28, 2016
Actual Study Completion Date : December 28, 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: LY03005
LY03005 80 mg
Drug: LY03005

Active Comparator: Pristiq
Pristiq 50 mg
Drug: Pristiq
Other Name: Desvenlafaxine

Primary Outcome Measures :
  1. Area under curve (AUC) for the Pharmacokinetics (PK) of LY03005 [ Time Frame: 4 days ]
    PK Samples drawn at 0 (within 30 minutes prior to dosing), 1,2,3,4 (+/- 5 min), 6,8,10,12,23,32,48 and 72 hours (+/- 15 min) after dosing.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Are capable of giving informed consent and complying with study procedures;
  2. Male and female subjects between the ages of 18 and 50 years;
  3. Considered healthy by the Principal Investigator, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs;
  4. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6 months before screening based on subject report;
  5. Body mass index (BMI) of 19 to 30 kg/m 2 inclusive and body weight not less than 50 kg;
  6. Willing and able to adhere to study restrictions and to be confined at the clinical research center.
  7. All female subjects no matter of age must have a negative pregnancy test result at screening. In addition, female subjects must meet one of the following three conditions: (i) postmenopausal for at least 2 years, (ii) surgically sterile based on subject report, or (iii) if child-bearing potential, practicing or agree to practice an effective method of birth control by using an acceptable method of contraception.

Acceptable methods of birth control include oral, injected, vaginal or patch contraceptive, IUD (Intrauterine device)(copper intrauterine device), or double- barrier method (e.g., condom, diaphragm or cervical cap with spermicidal foam, cream, gel or suppository). Acceptable methods of birth control must be used for at least 14 days prior to the use of study drug, during the study and within one month after the end of the study.

Exclusion Criteria:

  1. Clinically significant past history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, ophthalmological, or drug hypersensitivity;
  2. History of suicide attempt in the past 12 months and/or seen by the investigators having a significant history of risk of suicide or homicide;
  3. History or presence of malignancy other than adequately treated basal cell skin cancer;
  4. Clinically relevant illness within one month prior to the screening visit or at screening visit that may interfere with the conduct of this study;
  5. Subjects with a mean systolic blood pressure of three measurements >140 mmHg, or a mean diastolic blood pressure of three measurements >90 mmHg at screening;
  6. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody;
  7. A history of seizure. However, a history of febrile seizure is allowed;
  8. A hospital admission or major surgery within 30 days prior to screening;
  9. Participation in any other investigational drug trial within 30 days prior to screening;
  10. A history of prescription drug abuse, or illicit drug use within 6 months prior to screening;
  11. A history of alcohol abuse according to medical history within 6 months prior to screening;
  12. A positive screen for alcohol, drugs of abuse;
  13. Tobacco use within 6 months prior to screening based on subject report;
  14. Subjects with hypersensitivity to PRISTIQ or medicines containing desvenlafaxine or its precursor venlafaxine;
  15. Subjects who have participated in a previous clinical study of either LY03005 or PRISTIQ or medicines containing desvenlafaxine or its precursor, venlafaxine within 30 days prior to screening;
  16. An unwillingness or inability to comply with food and beverage restrictions during study participation;
  17. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 90 days prior to screening;
  18. Use of prescription or over-the-counter (OTC) medications, and herbal (including St John's Wort, herbal teas, garlic extracts) within 14 days prior to dosing (Note: Use of acetaminophen at < 3g/day is permitted until 24 hours prior to dosing).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02988024

Layout table for location information
United States, New Jersey
Clinilabs, Inc.
Eatontown, New Jersey, United States, 07724
Sponsors and Collaborators
Luye Pharma Group Ltd.
Layout table for investigator information
Study Chair: Simon Li, M.D. Luye Pharma Group Ltd.

Layout table for additonal information
Responsible Party: Luye Pharma Group Ltd. Identifier: NCT02988024     History of Changes
Other Study ID Numbers: LY03005/CT-USA-103
First Posted: December 9, 2016    Key Record Dates
Last Update Posted: March 20, 2017
Last Verified: March 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder, Major
Depressive Disorder
Mood Disorders
Mental Disorders
Desvenlafaxine Succinate
Serotonin and Noradrenaline Reuptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
Antidepressive Agents
Psychotropic Drugs